Press & Media

For any Press & Media inquiries regarding WCLC 2015 and/or IASLC, please contact:

IASLC Director of Communication
Jeff Wolf
Jeff.Wolf at

WCLC 2015 Newspaper

Press Conferences

Call In Information for all Press Conferences
*Note: All callers will remain muted for the duration of the press conference. If you wish to ask a question, you must type it into the chat window and staff will ask it if time allows.

  1. Registration & Meeting Link:
  2. TO USE YOUR COMPUTER’S AUDIO: When the webinar begins, you will be connected to audio using your computer’s microphone and speakers (VoIP). A headset is recommended. 
  3. TO USE YOUR TELEPHONE: If you prefer to use your  phone, you must select “Use Telephone” after joining the webinar and call in using the following numbers: 

Access Code: 258-204-757 / Audio PIN: Shown after joining the webinar

For more call in numbers, please click here >>

Press Conference 1

  • Please click here to view the presentation slides (pdf) from Press Conference 1
  • Date: Sunday, September 6, 2015
  • Time: 11:30 – 12:30 Mountain Time (MT)
  • Location: Colorado Convention Center, Room 108 + 110 + 112
  • Moderator: Dr. Harvey Pass, Congress Co-Chair,  Stephen E. Banner Professor of Thoracic Oncology, Division Chief of General Thoracic Surgery, and Vice Chair for Research for the Department of Cardiothoracic Surgery for the NYU Langone Medical Center
  • Agenda:
    • Introduction to WCLC, preview of Opening Ceremonies & Daily Theme - Dr. Fred R. Hirsch, IASLC CEO & Congress President
    • Summary of the IASLC Third CT Screening Workshop - Dr. John Field, Chair, SLCS Screening Advisory Committee
    • Summary of Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against Lung Cancer Session - Dr. ChunXue Bai, Session Chair
    • Advocacy and Patient Advocates - Janet Freeman-Daily, Lung Cancer Patient & Advocate
    • Q & A

Press Conference 2

  • Please click here to view the presentation slides (pdf) from Press Conference 2
  • Date: Monday, September 7, 2015
  • Time: 09:45 – 10:45 Mountain Time (MT)
  • Location: Colorado Convention Center, Room 108 + 110 + 112
  • Moderator: Dr. James Jett, Congress Co-Chair, Professor of Medicine at National Jewish Health in Denver, Colo. 
  • Agenda:
    • Daily Theme: Lung Cancer Prevention & Screening - Dr. Claudia Henschke, Professor of Radiology and head of Lung and Cardiac Screening Program at Mount Sinai Medical Center, New York
    • New Tobacco Declaration from IASLC - Dr. Kenneth Michael Cummings, Chair of Tobacco Control and Smoking Cessation Committee
    • Abstract – Impact of Time to Drug Approval on Potential Years of Life Lost: The Compelling Need for Improved Trial and Regulatory Efficiency - Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital
    • Abstract – Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2 - Dr. Philip Bonomi, Professor, Rush University Medical Center – Medical Oncology, Chicago, Ill.
    • Abstract – Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP in Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS Randomized Phase 3 Trial - Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France
    • Q & A

Press Conference 3

  • Please click here to view the presentation slides (pdf) from Press Conference 3
  • Date: Tuesday, September 8, 2015
  • Time: 09:45 – 10:45 Mountain Time (MT)
  • Location: Colorado Convention Center, Room 108 + 110 + 112
  • Moderator: Dr. Everett Vokes, Congress Co-Chair, John Ultmann Professor and Chair, Department of Medicine at the University of Chicago
  • Agenda:
    • Daily Theme: Lung Cancer: A Women’s Disease - Dr. Silvia Novello, Associate Professor, Department of Oncology, University of Turin-Italy
    • Revised (8th) Edition of TNM Staging System for Lung Cancer - Dr. Ramon Rami-Porta, Thoracic Surgery Service, Hospital Universitari Mutua Terrassa, Barcelona, Spain
    • 2015 WHO Classification of the Pathology and Genetics of Tumors of the Lung - Dr. William Travis, Attending Thoracic Pathologist, Dept. of Pathology, Memorial Sloan Kettering Cancer Center, New York
    • Abstract – Increasing Incidence of Non-Smoking Lung Cancer: Presentation of Patients with Early Disease to a Tertiary Institution in the UK - Dr. Eric Lim, Royal Brompton and Harefield NHS Trust, London
    • Abstract – Increasing Incidence of Never Smokers in Non Small Cell Lung Cancer (NSCLC) Patients - Dr. Lorraine Pelosof, Assistant Professor, UT Southwestern Medical Center, Dallas, Texas
    • Abstract – Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth - Dr. Kosuke Tanaka, Department of Cancer Genetics, Nagoya University Graduate School of Medicine; Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan
    • Abstract – The Genomics of Young Lung Cancer Study - Dr. Barbara Gitlitz, Associate Professor of Clinical Medicine at USC Keck School of Medicine, Los Angeles
    • Q & A

Press Conference 4

  • Please click here to view the presentation slides (pdf) from Press Conference 4
  • Date: Wednesday, September 9, 2015
  • Time: 09:45 – 10:45 Mountain Time (MT)
  • Location: Colorado Convention Center, Room 108 + 110 + 112
  • Moderator: Dr. Paul A. Bunn, Jr., former IASLC CEO, Distinguished Professor, Division of Medical Oncology at the University of Colorado Cancer Center of the Univ. of Colorado School of Medicine
  • Agenda:
    • Daily Theme: Science Drives Lung Cancer Advances - Dr. David R. Gandara, Professor of Medicine, Division of Hematology/Oncology, Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center, Sacramento, California
    • Abstract – Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505 - Dr. Heather Wakelee, Associate Professor of Medicine (Oncology) at the Stanford University Medical Center, Stanford, California
    • Abstract – Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography (LDCT) Screening Volunteers - Dr. Ugo Pastorino, Director Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
    • Abstract – Multiregion Whole Exome and Transcriptome Sequencing Defines the Genomic Spectrum of EGFR+ NSCLC and Reveals Novel Mechanisms of TKI Resistance - Dr. Daniel Shao Weng Tan, Consultant, Medical Oncology, National Cancer Centre, Singapore
    • Abstract – A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819 - Dr. Roy Herbst, Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director, Thoracic Oncology Research Program, Associate Director for Translational Research, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut
    • Abstract – EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous NSCLC - Dr. Fred R. Hirsch, IASLC CEO, Congress President, Professor of Medicine and Pathology, University of Colorado
    • Q & A

Onsite Press & Media Room

Colorado Convention Center, Room 212

Sunday, September 6 07:00 – 18:00 Mountain Time (MT)
Monday, September 7 07:00 – 18:00 Mountain Time (MT)
Tuesday, September 8 07:00 – 18:00 Mountain Time (MT)
Wednesday, September 9 07:00 – 18:00 Mountain Time (MT)

Wireless internet access, power bars and a copier are available in the Media Room to assist credentialed media representatives.



UPDATE: While we are releasing most abstracts on Aug. 21 at 4 p.m. Pacific Time, please refrain from sending out a news release or holding a press conference on the data contained in any abstracts until the date of the presentation at the 16th World Conference on Lung Cancer. Any entity may send out a release previewing the data and to announce its pending release at the WCLC. IASLC is withholding information for certain abstracts included in our press program. That information is forthcoming.

Other considerations:

  • Entities, such as pharmaceutical companies or medical institutions, may perform additional media efforts, including press releases or conferences, but materials may not be sent out during our press conferences or during any hours when WCLC presentations are ongoing. Additionally, all independent press conferences may not be held on-site.
  • Please contact the presenter of the data you wish to independently promote so as to respect their wishes regarding media outreach.
  • On Aug. 21, the released abstracts may be found in multiple locations on this website.
  • The embargo for abstracts does not change unless it is a part of our press program.
  • IASLC does not need to review any entity’s independent press release, but please consult with your presenter.
  • We discourage the distribution of independent materials in the press room. Please save this activity for our Exhibition Hall.

Abstract Embargo Policy

Abstracts will be made available online on Friday, August 21, 2015 at 4pm Pacific Time and in alignment with the release of the personal itinerary builder. Late-Breaking Abstracts and those abstracts scheduled for a press release will only have their titles and authors released on August 21, 2015 and the full abstracts will not be available until either presented at the WCLC 2015 or released during a press conference, whichever comes first. Once presented or released the full abstract will be available online.

Registrants will receive in their on-site registration material at the conference a USB drive containing the same material that was released on August 21, 2015.

All abstracts, including Late-Breaking and Press Release, will be published in the Journal of Thoracic Oncology as a supplement following the conference.

Press Kit

Media Registration

Registration Requirements

Journalists, including photographers, must work exclusively for the outlet for which they are credentialed (exceptions for freelance journalists are detailed below). Journalists who use their media privileges to work for non-credentialed organizations will have their privileges revoked. Journalists are required to complete the media registration form and submit the following:

  • A letter of assignment on the letterhead of the news organization being represented
  • Copies of 2 bylined medical/health/science articles (or credited photos) published within the last six months. Web links are acceptable, provided the full article is accessible.
  • A photocopy of official press credentials, such a press card issued by a recognized journalists’ association or a government-sanctioned press organization (IASLC does not recognize press cards issued by web-based organizations such as IFNM) and/or a business card issued by a recognized news organization

Freelance journalists including photographers may work for multiple publications, as long as they confirm in advance that those publications are eligible for media registration. Freelance journalists must submit the following: 

  • A letter of assignment on the letterhead of the news organization being represented
  • Copies of 2 bylined medical/health/science articles (or credited photos) published within the last six months. Web links are acceptable, provided the full article can be accessed.
  • A recent copy of the publication (a mailed copy, link to the publication’s website or a photocopy of a cover/issue published within the past 6 months).